Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Global Prevalence of Obesity in Patients With Psoriatic Arthritis in the Past Four Decades: An Analysis of Trends From 1984 to 2024.

  • 2026-02-04
  • Obesity reviews : an official journal of the International Association for the Study of Obesity 27(7)
    • Yuanting Yu
    • Jiao Wang
    • Xiaoying Sun
    • Liu Liu
    • Qingyun Wang
    • Pengbo Gao
    • Changxian Wang
    • Feng Li
    • Xin Li

Study Design

Type
Meta-Analysis
Population
patients with PsA
Methods
examined eight databases from inception to November 20, 2024; meta-analysis, meta-regression, subgroup analyses, funnel plots, Egger's test, trim-and-fill method

Background

Although the risk of psoriatic arthritis (PsA) and obesity comorbidities is increasing, only a few systematic global prevalence studies have been conducted.

Objective

This study explored the global prevalence of obesity, abdominal obesity, and being overweight in patients with PsA.

Methods

We examined eight databases from their inception to November 20, 2024. The R language was used for the data analysis. Meta-regression and subgroup analyses were used to evaluate the heterogeneity of the pooled studies. Funnel plots and Egger's tests were used to assess publication bias in the included studies, and the trim-and-fill method was used to correct for bias.

Results

Twenty-seven studies were included. The overall prevalence of obesity in patients with PsA was 35% (95% CI, 0.30 to 0.40). The prevalence of obesity in adults with PsA was 35% (95% CI, 0.28 to 0.42), and it was 27% (95% CI, 0.11 to 0.46) in children and adolescents. Africa had the highest prevalence (57%; 95% CI, 0.43 to 0.69). In contrast, the prevalence was the lowest in Europe at 31% (95% CI, 0.25 to 0.38). In terms of countries, China had the highest prevalence (65%), followed by Egypt (57%) and Norway (55%). The lowest prevalence was observed in the United States (20%).

Conclusions

These findings confirm the association between obesity and PsA. Considering the negative impact of obesity on PsA treatment, the early detection and management of obesity should be prioritized. Further population-based prospective observational studies are required to clarify the mechanisms underlying the coexistence of obesity in patients with PsA.

Research Insights

    Back to top